TY - JOUR
T1 - Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells
AU - de Bruin, Michiel
AU - Peters, Godefridus J
AU - Oerlemans, Ruud
AU - Assaraf, Yehuda G
AU - Masterson, Allan J
AU - Adema, Auke D
AU - Dijkmans, Ben A C
AU - Pinedo, Herbert M
AU - Jansen, Gerrit
PY - 2004/10
Y1 - 2004/10
N2 - Platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) and interleukin-8 (IL-8) are angiogenic factors produced by tumor infiltrating macrophages. Here, we show that prolonged exposure of human monocytic/macrophage THP1 and U937 cells to sulfasalazine, an anti-inflammatory drug and inhibitor of nuclear factor-kappaB (NF-kappaB), resulted in down-regulation of PD-ECGF/TP and IL-8 (mRNA, protein and activity) along with elimination of their induction by tumor necrosis factor-alpha and interferon-gamma. Concomitantly, sulfasalazine-exposed cells were markedly resistant to 5'-deoxyfluorouridine, the last intermediate of capecitabine requiring activation by PD-ECGF/TP. This is the first report suggesting that disruption of NF-kappaB-dependent signaling pathways can provoke a marked and sustained down-regulation of macrophage-related angiogenic factors. However, this may also negatively affect capecitabine efficacy.
AB - Platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) and interleukin-8 (IL-8) are angiogenic factors produced by tumor infiltrating macrophages. Here, we show that prolonged exposure of human monocytic/macrophage THP1 and U937 cells to sulfasalazine, an anti-inflammatory drug and inhibitor of nuclear factor-kappaB (NF-kappaB), resulted in down-regulation of PD-ECGF/TP and IL-8 (mRNA, protein and activity) along with elimination of their induction by tumor necrosis factor-alpha and interferon-gamma. Concomitantly, sulfasalazine-exposed cells were markedly resistant to 5'-deoxyfluorouridine, the last intermediate of capecitabine requiring activation by PD-ECGF/TP. This is the first report suggesting that disruption of NF-kappaB-dependent signaling pathways can provoke a marked and sustained down-regulation of macrophage-related angiogenic factors. However, this may also negatively affect capecitabine efficacy.
KW - Angiogenesis Inducing Agents/metabolism
KW - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
KW - Blotting, Western
KW - Gene Expression/drug effects
KW - Humans
KW - Interleukin-8/genetics
KW - Macrophages/drug effects
KW - Monocytes/cytology
KW - NF-kappa B/metabolism
KW - NF-kappa B p50 Subunit
KW - RNA, Messenger/metabolism
KW - Receptors, Interferon/metabolism
KW - Receptors, Tumor Necrosis Factor, Type I/metabolism
KW - Receptors, Tumor Necrosis Factor, Type II/metabolism
KW - Sulfasalazine/pharmacology
KW - Thymidine Phosphorylase/genetics
KW - Transcription Factor RelA
KW - Transcription Factors/metabolism
KW - U937 Cells
U2 - 10.1124/mol.104.000315
DO - 10.1124/mol.104.000315
M3 - Article
C2 - 15269287
SN - 0026-895X
VL - 66
SP - 1054
EP - 1060
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 4
ER -